A Phase 3 interventional study of somatropin and somatropin in Fetal Growth Retardation, sponsored by Sanofi. Completed at 1 site in France. Open to participants aged 3 Years to 11 Years. Per ClinicalTrials.gov, last updated 2010-10-05.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Fetal Growth Retardation with a site in France — 8 open to participants now, 8 under way, 2 of them phase 3. Fetal Growth Retardation · France.
Among the 29 studies in Fetal Growth Retardation with a site in France, this one is the 6th largest by enrollment of the 16 interventional ones that give a count, is one of 2 that started in 1993, is one of 7 in phase 3, and was the 2nd registered.
262 studies on the registry are indexed under Fetal Growth Retardation; 69 are open to participants now.
Browse Fetal Growth Retardation studies →8 of the 29 studies in Fetal Growth Retardation with a site in France are open now. Recruiting first, the newest first:
University Hospital, Strasbourg, France · Sites in France
Ages 18+ · Women only
Institut National de la Santé Et de la Recherche Médicale, France · Sites in France
Ages up to 5 mo · Healthy volunteers
Centre Hospitalier Universitaire de Nīmes · Sites in France
Ages 18+ · Women only
Central Hospital, Nancy, France · Sites in France
Ages 18–64 · Women only
University Hospital, Bordeaux · Sites in France
Ages 18+ · Women only
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 48 Fetal Growth Retardation studies recruiting now, 24 (50%) set no upper age limit and 21 (44%) stop at 75 or younger; 16 take children under 18; 24 take healthy volunteers.
This study: 3 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 1993; this study’s year is marked. 2 started in 1993.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 306 is above the median of 150 across 110 interventional studies indexed under Fetal Growth Retardation.
Median enrollment 207 across the 16 interventional studies, 220 across the 13 observational. Of the 16 that completed or were terminated, 2 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 29 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,560 studies on the registry; 91 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Sanofi has 1 study filed under Fetal Growth Retardation — fewer than ten, so there is no comparison to draw.
2 of the studies in Fetal Growth Retardation with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05674487University Hospital, BordeauxProstaglandins Versus Trans-cervical Balloon for Induction of Labor in Fetal Growth Restriction (PROBIN) | 2026-12-01 |
| NCT07864272University Hospital, Strasbourg, FranceAssessment of Invasive Genetic Testing in Fetuses With Isolated Intrauterine Growth Restriction Diagnosed After 28 Weeks of Gestation at Strasbourg University Hospitals (2016-2023) | 2026-12-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 29 studies in Fetal Growth Retardation with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Drug: somatropin
Drug: somatropin
0.2 IU/kg/day 7 days per week given sequentially (alternating periods of 6 months of treatment and 6 months of no treatment) for 3 years
0.2 IU/kg/day 7 days per week given continuously for 3 years
Efficacy data : measurement of height
Time frame: at trimestrial visit
laboratory test assessment and evaluation of bone age
Time frame: at every other visit
measurement of anti-GH and anti-ECP antibodies
Time frame: one visit out of four
Tolerance data : undesirable events
Time frame: throughout the study
The record gives a start of May 1993, a primary completion of Apr 2010 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human Growth Hormone